STOCK TITAN

aTyr Pharma regains Nasdaq bid-price compliance

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

aTyr Pharma (ATYR) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock’s closing bid price was $1.00 per share or greater for 10 consecutive business days, from October 30 through November 12, 2026. The company also stated that it had no outstanding deficiency notices from Nasdaq.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Minimum closing bid price $1.00 per share Nasdaq’s continued listing requirement; the stock met or exceeded this price during the compliance period.
Compliance period 10 consecutive business days October 30 through November 12, 2026.
Additional compliance period 180 days The period granted in June 2026 extended through November 30, 2026.
Initial period below minimum bid price 30 consecutive business days The period preceding the December 4, 2025 deficiency notice, during which the closing bid price was below $1.00 per share.
Nasdaq Listing Rule 5550(a)(2) regulatory
"regained compliance with Nasdaq Listing Rule 5550(a)(2)"
minimum closing bid price financial
"the minimum closing bid price required"
A minimum closing bid price is the lowest share price a stock must register at market close—often set by an exchange or regulator and sometimes measured over a series of days—to keep the stock listed. Think of it like a minimum score a team must maintain to stay in a league; falling below it can trigger warnings, delisting risk, or corporate fixes such as reverse stock splits, and so it matters because it affects liquidity, investor access and the value and tradability of shares.
continued listing requirements regulatory
"continued listing requirements of Nasdaq Listing Rule 5550(a)(2)"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.
market value of publicly held shares financial
"meeting the continued listing requirement for market value of publicly held shares"
The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did ATYR regain compliance with Nasdaq’s minimum bid-price rule?

Nasdaq determined that ATYR regained compliance after its common stock’s closing bid price was $1.00 per share or greater for 10 consecutive business days, from October 30 through November 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001339970false00013399702026-11-132026-11-13

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

 

ATYR PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-37378

20-3435077

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

10240 Sorrento Valley Road, Suite 300

San Diego, CA

 

 

 

92121

(Address of Principal Executive Offices)

 

 

(Zip Code)

Registrant’s telephone number, including area code: (858) 731-8389

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ATYR

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

 

Item 8.01

 

Other Events.

As previously disclosed, on December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). On June 3, 2026, the Company received a letter from the Staff (the “Letter”) notifying the Company that the Company is eligible for an additional 180-day period, or until November 30, 2026, to regain compliance, based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement. The Notice and the Letter had no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market.

On November 13, 2026, the Company received a letter from the Staff notifying the Company that the Staff has determined that for the last 10 consecutive business days, from October 30, 2026 to November 12, 2026, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). As of the date of this Current Report on Form 8-K, the Company has no outstanding deficiency notices from Nasdaq.

 

 

 

2


 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATYR PHARMA, INC.

By:

/s/ Brandon Yaras

Brandon Yaras

Chief Financial Officer

 

Date: November 13, 2026

 

 

3


Filing Exhibits & Attachments

1 document

Keep reading